4 recruiting, 2 completed, 2 withdrawn, 1 active not recruiting. 8 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 4, Active not recruiting 1, Completed 1, Enrolling by invitation 1, Terminated 1 |
| Phase 1 | 5 | Completed 2, Withdrawn 2, Enrolling by invitation 1 |
Follow Zenith Epigenetics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The COSMYC Trial (COmbined Suppression of MYC) ZEN-3694, Testosterone cypionate, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2025-08-19 | 2026-06-18 |
| ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors ZEN003694, Niraparib - Ovarian Cancer, Recurrent Solid Tumors | Phase 1 | Withdrawn | Haider Mahdi | 2024-01-23 | 2024-10-15 | |
| ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer ZEN003694, Talazoparib - Ovarian Cancer, Peritoneal Cancer | Phase 2 | Recruiting | Alexander B Olawaiye, MD | 33 | 2023-04-21 | 2026-06-18 |
| A Study of ZEN003694 in People With Squamous Cell Lung Cancer ZEN003694 - Squamous Cell Lung Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 13 | 2022-11-01 | 2026-09-23 |
| ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer ZEN003694, Enzalutamide - Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Recruiting | Zenith Epigenetics | 200 | 2021-09-08 | 2026-05-08 |
| ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer BET Bromodomain Inhibitor ZEN-3694, Enzalutamide, Pembrolizumab - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Active not recruiting | Rahul Aggarwal | 61 | 2021-01-26 | 2026-07-23 |
| Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol ZEN003694, Enzalutamide - mCRPC | Phase 1 / Phase 2 | Enrolling by invitation | Zenith Epigenetics | 40 | 2019-11-12 | 2026-05-08 |
| A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer ZEN003694, Talazoparib - Triple Negative Breast Cancer | Phase 2 | Terminated | Zenith Epigenetics | 115 | 2019-06-26 | 2025-10-07 |
| A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer ZEN003694, Enzalutamide - Metastatic Castration-Resistant Prostate Cancer | Phase 1 / Phase 2 | Completed | Zenith Epigenetics | 75 | 2016-12-01 | 2021-11-30 |
| A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer ZEN003694 - Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Completed | Zenith Epigenetics | 44 | 2016-05-01 | 2017-11-20 |
| Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML ZEN003365 - Lymphoproliferative Malignancies, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Zenith Epigenetics | 2014-10-01 | 2014-11-13 |
Prostatic Neoplasms (5) · Ovarian Neoplasms (2) · Breast Neoplasms (1) · Fallopian Tube Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Prolymphocytic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Neoplasm Metastasis (1) · Recurrence (1)
enzalutamide (5) · talazoparib (2) · Gonadotropin-Releasing Hormone (1) · Goserelin (1) · Leuprolide (1) · Triptorelin Pamoate (1) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (1) · luprolide acetate gel depot (1) · niraparib (1) · pembrolizumab (1) · relugolix (1) · testosterone 17 beta-cypionate (1)
United States (11) · China (2) · Belgium (1) · Spain (1)
Alexander B Olawaiye, MD (1) · Haider S Mahdi, MD (1) · Paul Paik, MD (1) · Rahul R Aggarwal, MD (1) · Samuel Denmeade, MD (1)
2018 (1), P50CA272391 (1)